10-Q: Aditxt Faces Going Concern Doubts Amid Mounting Losses

Aditxt, Inc. reports a significant net loss and negative cash flow for Q3 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Aditxt, Inc. reported a net loss of $37,555,792 for the nine months ended September 30, 2025, an increase from $29,472,886 in the prior year period.
• Cash and cash equivalents stood at $163,041 as of September 30, 2025, down from $833,031 at December 31, 2024.
• The company experienced negative cash flow from operating activities of $16,442,686 for the nine months ended September 30, 2025.
• Revenue for the nine months ended September 30, 2025, was $2,770, a substantial decrease from $130,810 in the same period of 2024, primarily due to decreased AditxtScore™ orders from reduced COVID testing.
• An accumulated deficit of $205,107,091 was reported as of September 30, 2025.
• The company's investment in Evofem F-1 Preferred Stock was impaired by $23,001,919, reducing its value from $27,277,211 to $7,051,933.
• The merger agreement with Evofem Biosciences, Inc. was terminated on October 20, 2025, due to the end date passing and failure to obtain shareholder approval.
• The Exclusive Worldwide Sublicense Agreement for AditxtScore technology with Pearsanta was terminated on September 23, 2025.
• Aditxt is over 90 days past due on approximately $9.1 million of its $11.6 million in accounts payable and accrued expenses.
• All lab equipment financing agreements are matured and in default status as of September 30, 2025.
• The company is in arrears on two significant leases: two months for its Mountain View, CA headquarters and five months for its Richmond, VA laboratory facility.
• Three reverse stock splits were effectuated: 1-for-40 on October 2, 2024, 1-for-250 on March 14, 2025, and 1-for-113 on November 3, 2025.
• The company continues to pursue capital raising transactions, including sales of common stock through an At The Market (ATM) offering and an Equity Line of Credit (ELOC).

Sentiment

Score: 1

Explanation: The company is in severe financial distress, evidenced by a substantial net loss, negative cash flow, a 'going concern' warning, significant accumulated deficit, multiple defaults on obligations, and terminated strategic agreements. While there is some preclinical progress, the overall financial health and operational execution are extremely poor.

Positives

• Preclinical studies for ADI-100 (immune modulation therapeutic) have been completed, showing potential effectiveness in type-1 diabetes, psoriasis, and multiple sclerosis, with no drug toxicity or impairment of the immune system.
• GMP clinical-grade drug substances for ADI-100 have been successfully manufactured, with clinical trials planned in Germany for psoriasis and type 1 diabetes.
• Adimune is working with the Mayo Clinic to prepare an IND package for FDA submission for ADI-100, with a pre-IND meeting expected in Q2 2026.
• Pearsanta, a majority-owned subsidiary, acquired the Mitomic Technology platform, patents, and intellectual property, positioning it for research and discovery of mitochondrial DNA-based biomarkers for early cancer detection.
• Pearsanta has two product candidates in development: Mitomic Prostate Test (MPT) and Mitomic Endometriosis Test (MET), and has identified biomarkers for ovarian and lung cancer.
• Pearsanta acquired Adductomics Technology for DNA adduct detection, aiming to provide insights into DNA damage and cancer risk, with development expected over the next two to three years.

Negatives

• Net loss increased to $37,555,792 for the nine months ended September 30, 2025, from $29,472,886 in the prior year period.
• Cash balance significantly decreased to $163,041 as of September 30, 2025, from $833,031 at December 31, 2024.
• Negative cash flow from operating activities increased to $16,442,686 for the nine months ended September 30, 2025.
• Revenue plummeted to $2,770 for the nine months ended September 30, 2025, from $130,810 in the prior year, primarily due to decreased AditxtScore™ orders.
• The company has an accumulated deficit of $205,107,091 as of September 30, 2025.
• A $23,001,919 impairment loss was recognized on the investment in Evofem F-1 Preferred Stock.
• The merger agreement with Evofem Biosciences, Inc. was terminated, indicating a failure in a significant strategic initiative.
• The Exclusive Worldwide Sublicense Agreement for AditxtScore technology with Pearsanta was terminated.
• Approximately $9.1 million of the company's $11.6 million in accounts payable and accrued expenses are over 90 days past due.
• All lab equipment financing agreements are matured and in default status.
• The company is two months in arrears on its Mountain View, CA headquarters lease and five months in arrears on its Richmond, VA laboratory lease.
• The company owes a remaining $1,000,000 termination fee related to the Appili Arrangement Agreement termination.
• Multiple reverse stock splits (1-for-40, 1-for-250, 1-for-113) indicate severe stock price depreciation and significant dilution for existing shareholders.

Risks

• The company has generated no significant revenue from commercial sales to date, and future profitability is uncertain.
• Failure to obtain necessary capital to fund operations will prevent product development and likely lead to a loss of the entire investment.
• The company's financial situation creates substantial doubt about its ability to continue as a going concern.
• Additional funding may not be available on acceptable terms, or at all, and even if available, may be dilutive to shareholders.
• The regulatory approval process for product candidates is expensive, time-consuming, and uncertain.
• Substantial delays in completing clinical studies will require additional costs, or the company may fail to demonstrate adequate safety and efficacy.
• Even with regulatory approval, the company may not successfully commercialize product candidates, limiting revenue.
• Adverse events involving products could lead to regulatory delays, denials, or product recalls.
• Licenses from Loma Linda University (LLU) and Stanford are revocable if certain payments and milestone deadlines are not met.
• Loss of CLIA certification or state laboratory licenses would prevent the company from offering its assays, harming revenues and business.
• The company faces substantial competition from larger, more well-funded companies.
• Failure to obtain or maintain patents, licensing agreements, and other intellectual property could materially impact competitive ability.
• Significant dilution may occur from the conversion and/or exercise of convertible preferred stock, warrants, restricted stock awards, and equity lines.
• The company's ability to remain compliant with Nasdaq Capital Market listing requirements is at risk, and delisting could adversely affect stock value and liquidity.
• Default on secured obligations could lead to creditors foreclosing on assets, harming financial condition and potentially forcing bankruptcy protection.
• The company is currently over 90 days past due on a significant amount of vendor obligations, which could lead to further defaults and legal actions.

Future Outlook

The company expects to incur additional net expenses for the foreseeable future and may never become profitable. It will require significant additional capital to fund operations and clinical trials, actively pursuing equity or debt financing through private placements, public offerings, or related party loans. The company believes its current cash reserves are insufficient to fund operations for the next 12 months, creating substantial doubt about its ability to continue as a going concern. The ability to raise capital is subject to market conditions, stock price, volatility, trading volume, demand, and regulatory requirements.

Management Comments

• "We believe the world needs—and deserves—a new approach to innovating that harnesses the power of large groups of stakeholders who work together to ensure that the most promising innovations make it into the hands of people who need them most."
• "The socialization of innovation through engaging stakeholders in every aspect of it, is key to transforming more innovations, more rapidly, and more efficiently."
• "We believe our remaining funds on hand will not be sufficient to fund our operations for the foreseeable future."
• "Because of these factors, we believe that this creates substantial doubt with the Companys ability to continue as a going concern."

Industry Context

Aditxt operates in the high-risk, high-reward biotechnology sector, focusing on immune modulation therapeutics (Adimune's ADI-100) and early cancer detection diagnostics (Pearsanta's Mitomic Technology and Adductomics). This industry is characterized by extensive research and development costs, lengthy and uncertain regulatory approval processes, and intense competition from larger, well-funded companies. The company's 'innovation platform' model aims to democratize innovation, but its current financial distress, including significant losses, negative cash flow, and terminated strategic partnerships (Evofem, Appili, Pearsanta AditxtScore sublicense), indicates severe challenges in commercializing its pipeline and securing sustainable funding within this demanding landscape. The reliance on frequent dilutive capital raises is a common, but often unsustainable, characteristic of early-stage biotech firms struggling to reach profitability.

Comparison to Industry Standards

• The company's financial performance, characterized by minimal revenue ($2,770 for nine months), substantial net losses ($37.5 million), and negative working capital ($20.2 million), is significantly below the commercialization and profitability standards of established biotechnology companies.
• The repeated reverse stock splits (1-for-40, 1-for-250, 1-for-113) are indicative of severe stock price underperformance and are not typical for healthy, growing companies in the biotech sector, often signaling distress or delisting risk.
• The 'going concern' warning, coupled with defaults on vendor obligations ($9.1 million over 90 days past due), lease payments, and matured financing agreements, places the company in a precarious financial position far below industry norms for operational stability.
• While preclinical progress for ADI-100 and the development of cancer detection candidates (MPT, MET) are positive scientific steps, the lack of initiated human clinical trials for ADI-100 (despite prior milestones) and the early stage of Pearsanta's products mean the company is far from generating significant commercial revenue, unlike more advanced biotech peers with products in later-stage trials or on the market.
• The termination of the Evofem merger and the Appili agreement, along with the internal sublicense termination with Pearsanta, suggests difficulties in executing strategic partnerships and commercialization strategies, which are critical for growth in the biotech industry.

Corporate Governance

Legal Proceedings

• The company may become involved in various lawsuits and legal proceedings in the ordinary course of business, with inherent uncertainties and potential adverse results.

Related Party Transactions

• On May 22, 2025, Amro Albanna (CEO) loaned $233,000 to the company, which was fully paid off by September 30, 2025.
• On June 6, 2025, Shahrokh Shabahang (CIO) loaned $70,000 to the company, which was fully paid off by September 30, 2025.
• On June 20, 2025, Amro Albanna (CEO) and Shahrokh Shabahang (CIO) loaned $90,000 and $100,000, respectively, to the company, which were fully paid off by September 30, 2025.
• On August 13, 2025, Amro Albanna (CEO) and Shahrokh Shabahang (CIO) loaned $95,000 and $90,000, respectively, to the company, with an outstanding principal balance of $185,000 as of September 30, 2025. These notes were fully paid off by November 7, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution from ongoing equity raises (ATM, ELOC) and multiple reverse stock splits. The 'going concern' warning and substantial losses pose a high risk of further value erosion or complete loss of investment.
• **Employees**: The company's financial instability and need for capital raises could impact job security, compensation, and morale, although payroll expenses are noted.
• **Customers**: Decreased AditxtScore™ orders due to reduced COVID testing indicate a decline in service utilization, potentially impacting future revenue streams.
• **Suppliers/Creditors**: The company is over 90 days past due on approximately $9.1 million in vendor obligations and has defaulted on several financing and lease agreements, indicating high credit risk and potential for legal action.
• **Regulatory Authorities**: The company's financial condition and delays in clinical trial milestones could draw increased scrutiny from regulatory bodies like the FDA and Nasdaq.

Next Steps

• Continue actively pursuing capital raising transactions to meet existing and longer-term capital needs.
• Advance ADI-100 clinical trials in Germany for psoriasis and type 1 diabetes, managed by a Contract Research Organization (CRO).
• Prepare and submit an IND package for FDA submission for ADI-100, with a pre-IND meeting expected in Q2 2026.
• Initiate a human trial for Stiff Person Syndrome (SPS) with Mayo Clinic in 2026, enrolling 10-20 patients to test ADI-100 safety and efficacy.
• Continue leveraging Mitomic Technology to discover mitochondrial DNA-based biomarkers for various cancers.
• Further technical development and clinical validation for Mitomic Prostate Test (MPT) and Mitomic Endometriosis Test (MET).
• Further validation of the Adductomics Technology and creation of commercially available diagnostic kits over the next two to three years.
• Work with landlords to resolve arrears on office and laboratory leases.
• Remediate identified material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

The company's financial condition is extremely precarious, with a stated 'substantial doubt' about its ability to continue as a going concern. It reported a significant net loss of $37.5 million, negative cash flow from operations, and a critically low cash balance of $163,041. The company is in default on numerous obligations, including $9.1 million in accounts payable, all lab equipment financing, and two major leases. Key strategic initiatives, such as the Evofem merger and the Pearsanta sublicense, have been terminated, and a substantial impairment loss was recognized on the Evofem investment. The repeated, severe reverse stock splits indicate a desperate attempt to maintain listing compliance and have resulted in significant shareholder dilution. While there is preclinical progress in some areas, the company's severe liquidity issues, inability to generate meaningful revenue, and ongoing need for highly dilutive capital raises present an unacceptably high risk for investors. The likelihood of further capital erosion or bankruptcy is substantial.

Keywords

Biotechnology, Immune Modulation, Cancer Detection, Autoimmune Diseases, Organ Transplants, Diagnostics, SEC Filing, 10-Q, Financial Results, Going Concern, Clinical Trials, ADI-100, Mitomic Technology, AditxtScore, Evofem, Pearsanta, Nasdaq